Last reviewed · How we verify
Lymphodepletion Conditioning
Lymphodepletion conditioning involves the use of chemotherapy or radiation to deplete the immune system, making it more receptive to stem cell or bone marrow transplants.
Lymphodepletion conditioning involves the use of chemotherapy or radiation to deplete the immune system, making it more receptive to stem cell or bone marrow transplants. Used for Autologous hematopoietic stem cell transplantation for multiple myeloma, Allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia.
At a glance
| Generic name | Lymphodepletion Conditioning |
|---|---|
| Sponsor | Qingdao Sino-Cell Biomedicine Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
This process is typically used in the treatment of various blood cancers and disorders, such as leukemia and lymphoma. The goal of lymphodepletion is to reduce the immune system's ability to reject the transplanted cells, allowing them to engraft and produce healthy blood cells.
Approved indications
- Autologous hematopoietic stem cell transplantation for multiple myeloma
- Allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
- Safety and Efficacy of OBX-115 in Advanced Solid Tumors (PHASE1, PHASE2)
- Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases (PHASE1)
- Safety of PiggyBac Transposon CAR T-cells Targeting CD-19 in Refractory Lupus. (PHASE1)
- A Study to Assess CLBR001+SWI019 in Subjects With Autoimmune Diseases (PHASE1)
- A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis (PHASE1)
- An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors. (EARLY_PHASE1)
- Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease (PHASE1, PHASE2)
- SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lymphodepletion Conditioning CI brief — competitive landscape report
- Lymphodepletion Conditioning updates RSS · CI watch RSS
- Qingdao Sino-Cell Biomedicine Co., Ltd. portfolio CI